ArticleBioconjugate chemistry2009
Release of liposomal contents by cell-secreted matrix metalloproteinase-9.
Article in Bioconjugate chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 73 citations in OpenAlex.
- The Tumor Proteolytic Landscape: A Challenging Frontier in Cancer Diagnosis and Therapy.International journal of molecular sciences · 2021Review
- Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery.Expert opinion on drug delivery · 2021Review
- Real-time tracking of single-molecule collagenase on native collagen and partially structured collagen-mimic substrates.Chemical communications (Cambridge, England) · 2018Article
- Stimuli-responsive liposomes for drug delivery.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.Journal of controlled release : official journal of the Controlled Release Society · 2017Review
- From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers.Angewandte Chemie (International ed. in English) · 2017Review
- Enzyme-Responsive Liposomes for the Delivery of Anticancer Drugs.Bioconjugate chemistry · 2017Review
- Implantable Sensors for Regenerative Medicine.Journal of biomechanical engineering · 2017Review
- Nanomedicine applications in the treatment of breast cancer: current state of the art.International journal of nanomedicine · 2017Review
- Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Pharmacological reviews · 2016Review
- Engineering nanoparticles to overcome barriers to immunotherapy.Bioengineering & translational medicine · 2016Review
- Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer.Molecular pharmaceutics · 2014Article
- Encapsulated microbubbles and echogenic liposomes for contrast ultrasound imaging and targeted drug delivery.Computational mechanics · 2014Article
- Article
- Stimuli-responsive nanocarriers for drug delivery.Nature materials · 2013Review
- Current trends in the use of liposomes for tumor targeting.Nanomedicine (London, England) · 2013Review
- Polymer-coated echogenic lipid nanoparticles with dual release triggers.Biomacromolecules · 2013Article
- Human NAD(P)H:quinone oxidoreductase type I (hNQO1) activation of quinone propionic acid trigger groups.Biochemistry · 2012Article
- Advances in biomimetic regeneration of elastic matrix structures.Drug delivery and translational research · 2012Article
- Ultrasound enhanced matrix metalloproteinase-9 triggered release of contents from echogenic liposomes.Molecular pharmaceutics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Liposomes have been widely used as a drug delivery vehicle, and currently, more than 10 liposomal formulations are approved by the Food and Drug Administration for clinical use. However, upon targeting, the release of the liposome-encapsulated contents is usually slow. We have recently demonstrated that contents from appropriately formulated liposomes can be rapidly released by the cancer-associated enzyme matrix metalloproteinase-9 (MMP-9). Herein, we report our detailed studies to optimize the liposomal formulations. By properly selecting the lipopeptide, the major lipid component, and their relative amounts, we demonstrate that the contents are rapidly released in the presence of cancer-associated levels of recombinant human MMP-9. We observed that the degree of lipid mismatch between the lipopepides and the major lipid component profoundly affects the release profiles from the liposomes. By utilizing the optimized liposomal formulations, we also demonstrate that cancer cells (HT-29) which secrete low levels of MMP-9 failed to release a significant amount of the liposomal contents. Metastatic cancer cells (MCF7) secreting high levels of the enzyme rapidly release the encapsulated contents from the liposomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.